Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: Involvement of mammalian target of Rapamycin/eIF4E pathway

被引:107
|
作者
Pervin, Shehla
Singh, Rajan
Hernandez, Estebes
Wu, Guoyao
Chaudhuri, Gautam
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA
[3] Charles R Drew Univ Med & Sci, Div Endocrinol, Los Angeles, CA 90059 USA
[4] Charles R Drew Univ Med & Sci, RCMI Mol Med Core Lab, Los Angeles, CA 90059 USA
[5] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[6] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA
关键词
D O I
10.1158/0008-5472.CAN-05-4623
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nitric oxide (NO) in nanomolar (nmol/L) concentrations is consistently detected in tumor microenvironment and has been found to promote tumorigenesis. The mechanism by which NO enhances tumor progression is largely unknown. In this study, we investigated the possible mechanisms and identified cellular targets by which NO increases proliferation of human breast cancer cell lines MDA-MB-231 and MCF-7. DETA-NONOate, a long acting NO donor, with a half-life of 20 h, was used. We found that NO (nmol/L) dramatically increased total protein synthesis in MDA-MB-231 and MCF-7 and also increased cell proliferation. NO specifically increased the translation of cyclin D1 and ornithine decarboxylase (ODC) without altering their mRNA levels or half-lives. Critical components in the translational machinery, such as phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets, phosphorylated eukaryotic translation initiation factor and p70 S6 kinase, were up-regulated following NO treatment, and inhibition of mTOR with rapamycin attenuated NO induced increase of cyclin D1 and ODC. Activation of translational machinery was mediated by NO-induced up-regulation of the Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase/ERK (Raf/MEK/ERK) and phosphatidylinositol 3-kinase (PI-3 kinase)/Akt signaling pathways. Up-regulation of the Raf/MEK/ ERK and PI-3 kinase/Akt pathways by NO was found to be mediated by activation of Ras, which was cyclic guanosine 3',5'-monophosphate independent. Furthermore, inactivation of Ras by farnesyl transferase inhibitor or K-Ras small interfering RNA attenuated NO-induced increase in proliferation signaling and cyclin D1 and ODC translation, further confirming the involvement of Ras activation during NO-induced cell proliferation.
引用
收藏
页码:289 / 299
页数:11
相关论文
共 10 条
  • [1] Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway
    Nathan, CAO
    Amirghahari, N
    Abreo, F
    Rong, XH
    Caldito, G
    Jones, ML
    Zhou, HJ
    Smith, M
    Kimberly, D
    Glass, J
    CLINICAL CANCER RESEARCH, 2004, 10 (17) : 5820 - 5827
  • [2] Mammalian target of rapamycin (mTOR) and eIF4E regulate stearoyl CoA desaturase 1 expression through modulation of SREBP1 in breast cancer cell lines
    Luyimbazi, David
    Akcakanat, Argun
    Zhang, Li
    Zheng, Yuhuan
    Meric-Bernstam, Funda
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 209 (03) : S120 - S120
  • [3] eIF4E Expression Predicts Apoptosis in Response to Epidermal Growth Factor Receptor Inhibition and Mammalian Target of Rapamycin Inhibition in Triple Negative Breast Cancers
    Liu, T.
    Yacoub, R.
    Sun, S-Y
    Graham, T.
    Tighiouart, M.
    Yang, L.
    O'Regan, R. M.
    CANCER RESEARCH, 2009, 69 (24) : 791S - 791S
  • [4] Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells
    Wan, Jing
    Shi, Fang
    Xu, Zhanzhan
    Zhao, Min
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (06) : 2217 - 2225
  • [5] Translational control of lung cancer: eIF4E over-expression is not sufficient to confer tumorigenicity to human bronchial epithelial cells
    McCauley, Joel
    Jacobson, Blake
    Bitterman, Peter
    Kratzke, Robert
    D'Cunha, Jonathan
    CANCER RESEARCH, 2010, 70
  • [6] Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells
    Fei-fei Zhou
    Min Yan
    Gui-fang Guo
    Fang Wang
    Hui-juan Qiu
    Fei-meng Zheng
    Yan Zhang
    Qiang Liu
    Xiao-feng Zhu
    Liang-ping Xia
    Medical Oncology, 2011, 28 : 1302 - 1307
  • [7] Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells
    Zhou, Fei-fei
    Yan, Min
    Guo, Gui-fang
    Wang, Fang
    Qiu, Hui-juan
    Zheng, Fei-meng
    Zhang, Yan
    Liu, Qiang
    Zhu, Xiao-feng
    Xia, Liang-ping
    MEDICAL ONCOLOGY, 2011, 28 (04) : 1302 - 1307
  • [8] ENHANCED CELL PROLIFERATION AND INCREASED RESISTANCE TO MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS BY INHIBITION OF 4E-BINDING PROTEIN 1 EXPRESSION IN HUMAN RENAL CELL CARCINOMA ACHN CELLS
    Miyazaki, Akira
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2015, 193 (04): : E456 - E456
  • [9] The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
    Hoang, Bao
    Benavides, Angelica
    Shi, Yijiang
    Yang, Yonghui
    Frost, Patrick
    Gera, Joseph
    Lichtenstein, Alan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (26) : 21796 - 21805
  • [10] Everolimus Reverses Palbociclib Resistance in ER plus Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
    Chen, Lin
    Yang, Guangsheng
    Dong, Hongming
    MEDICAL SCIENCE MONITOR, 2019, 25 : 77 - 86